However, because the lung is the first-pass organ for intravenously infused effector cells, when intending to treat lung cancer, CCL2 at tumor sites in the lung field would preferentially attract such infused effector cells to a much greater extent than CCL2 expressed physiologically in other peripheral tissues. Here, CCL2 is linked to lung cancer.